Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 759 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: End Stage Renal Disease Clear all

Conditions: End-Stage Renal Disease (ESRD)
Interventions: EPN-701 (Oral); Drug
Lead sponsor: Epizon Pharma, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: End-Stage Renal Disease
Interventions: exposure to a high-calcium dialysate bath; Procedure
Lead sponsor: James B. Wetmore, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: End Stage Renal Disease
Interventions: Relaxation and guided imagery program; Behavioral
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Hyperphosphatemia, End Stage Renal Disease
Interventions: Tenapanor, Sevelamer Carbonate; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: Not listed
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, California

Conditions: Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions: FLAIR Endovascular Stent Graft, PTA; Device · Procedure
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bamberg, South Carolina

Conditions: Secondary Hyperparathyroidism
Interventions: Sensipar (Cinacalcet HCl); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more

Conditions: End-stage Renal Disease, Malnutrition; Protein
Interventions: Intradialytic Parenteral Nutrition; Other
Lead sponsor: Patient Care America; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Transplantation, End Stage Renal Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 8,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Hyperphosphatemia, End-Stage Renal Disease
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 15
States / cities: Westminster, Colorado • Pembroke Pines, Florida • Augusta, Georgia + 10 more

Conditions: Kidney Failure, Chronic
Interventions: Prehabilitation; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: End Stage Renal Disease, Hypoalbuminemia, Malnutrition
Interventions: Protein Food Bar Intelligent Indulgence; Dietary Supplement
Lead sponsor: Satellite Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Mountain View, California

Conditions: Uremic Pruritus
Interventions: PA101B, Placebo; Drug
Lead sponsor: Patara Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Northridge, California + 10 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Epoetin Alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 89
States / cities: Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more

Conditions: End Stage Kidney Disease
Interventions: Continuous glucose monitoring (CGM); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: End Stage Renal Disease, Depression
Interventions: Cognitive behavioral therapy; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: End Stage Renal Disease
Interventions: Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more

Conditions: Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Houston, Texas

Conditions: End Stage Renal Disease
Interventions: Expedial Vascular Access Graft; Device
Lead sponsor: LeMaitre Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Miami, Florida • Baton Rouge, Louisiana • The Bronx, New York + 4 more

Conditions: End Stage Renal Disease, Chronic Kidney Disease, Sleep Disorder
Interventions: Melatonin; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Secondary Hyperparathyroidism
Interventions: Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 8
States / cities: Downey, California • Paramount, California • Hudson, Florida + 5 more

Conditions: End Stage Renal Disease (ESRD), Brachiocephalic Fistula (BCF), Cephalic Arch Stenosis (CAS), Dialysis
Interventions: brachiocephalic fistula (BCF); Other
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

A Guided Meditation Program in Patients Undergoing Dialysis

Optimizing Kidney Transplant Informed Consent

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Post-Approval Study for the FLAIR Endovascular Stent Graft

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Live Kidney Donor Study

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Prehabilitation for Adults With End Stage Renal Disease on the Kidney Transplant Waitlist

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

Treatment of Uremic Pruritus With PA101B

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Outcome of BCF Access in Hemodialysis Patients